Finished
Mobility and Therapeutic Benefits Resulting From Exoskeleton Use in a Clinical Setting (SC140121 Study 1 and 2)
NCT03082898 · Vanderbilt University · Updated 16 Feb 2022
- What is being tested
- Indego Exoskeleton
- For
- Spinal Cord Injury
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 41 people. The full rules are on the registry page.
- Where
- United States (3 sites)
- When
- Starts or started 15 Nov 2016, ends 1 June 2020. Registered 17 March 2017.
- Results
- Posted on the registry on 16 Feb 2022.
In the researchers' words
The proposed study is intended to inform the hypotheses that (1) regular dosing of exoskeleton walking will provide health benefits to non-ambulatory and poorly-ambulatory individuals with SCI, including decreased pain and spasticity, improvements in bowel and bladder function, decreased body-mass index (BMI), enhanced well-being; (2) regular dosing of exoskeleton walking will facilitate neurological or functional recovery in some individuals with SCI, particularly those with incomplete injuries; and (3) the level of mobility enabled by a lower limb exoskeleton is commensurate with the walking speeds, distances, and surfaces required for community ambulation.
Sites
- Tampa VATampa, Florida, United States
- Mayo ClinicRochester, Minnesota, United States
- VanderbiltNashville, Tennessee, United States